@article{36f09b9c94b14e06b82fb3d8b36b7e53,
title = "Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: Mechanism of action in the context of efficacy and safety",
abstract = "Chronic pain continues to be a significant global burden despite the availability of a variety of nonpharmacologic and pharmacologic treatment options. Thus, there is a need for new analgesics with novel mechanisms of action. In this regard, antibodies directed against nerve growth factor (NGF-Abs) are a new class of agents in development for the treatment of chronic pain conditions such as osteoarthritis and chronic low-back pain. This comprehensive narrative review summarizes evidence supporting pronociceptive functions for NGF that include contributing to peripheral and central sensitization through tropomyosin receptor kinase A activation and stimulation of local neuronal sprouting. The potential role of NGF in osteoarthritis and chronic low-back pain signaling is also examined to provide a mechanistic basis for the observed efficacy of NGF-Abs in clinical trials of these particular pain states. Finally, the safety profile of NGF-Abs in terms of common adverse events, joint safety, and nerve structure/function is discussed.",
keywords = "Chronic low-back pain, Chronic pain, Mechanism of action, Nerve growth factor, Osteoarthritis",
author = "Martin Schmelz and Patrick Mantyh and Malfait, {Anne Marie} and John Farrar and Tony Yaksh and Leslie Tive and Lars Viktrup",
note = "Funding Information: Medical writing support was provided by Matt Soulsby, PhD, CMPP, of Engage Scientific Solutions and was funded by Eli Lilly and Co and Pfizer Funding Information: Medical writing support was provided by Matt Soulsby, PhD, CMPP, of Engage Scientific Solutions and was funded by Eli Lilly & Co and Pfizer. Funding Information: M. Schmelz declares personal fees from Pfizer as consultant in an NGF advisory board. P. Mantyh reports grants from National Institute of Health during the conduct of the study; personal fees and other from Pfizer outside the submitted work; and a patent anti-NGF for the relief of bone cancer pain issued. J. Farrar reports personal fees from Pfizer, Daiichi Sankyo, Cara Therapeutics, Biogen, Aptynx, Campbell Alliance, NIH-NIAMS, Analgesic Solutions, Novartis, Aptynyx, DepoMed, Jansen, Evadera, and from Wolhers Kluwer Health, outside the submitted work. L. Tive is a full-time employee of, and owns stock/option in, Pfizer Inc. L. Viktrup is a full-time employee of Eli Lilly & Co. The remaining authors have no conflicts of interest to declare. Publisher Copyright: {\textcopyright} Copyright 2019 The Author(s). Published by Wolters Kluwer Health, Inc.",
year = "2019",
month = oct,
day = "1",
doi = "10.1097/j.pain.0000000000001625",
language = "English (US)",
volume = "160",
pages = "2210--2220",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "10",
}